Trials / Not Yet Recruiting
Not Yet RecruitingNCT07357948
Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy
Omission of Surgery for Triple-negative Breast Cancer in Complete Response Confirmed by MRI and Macrobiopsy After Neoadjuvant Chemo-immunotherapy: a Randomized, Multicenter Phase II Trial.
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Institut Curie · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical study aims to determine if skipping breast and axillary surgery could provide similar control of local and distant disease, with fewer complications and better quality of life, for triple-negative breast cancer patients in complete response after neoadjuvant chemo-immunotherapy. Patients will be randomised into 2 groups : * Control arm will receive the standard treatment, including surgery * Experimental arm will receive the standard treatment, except surgery
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Omission of surgery | Patients will not undergo breast and axillary surgery. |
Timeline
- Start date
- 2026-08-01
- Primary completion
- 2031-07-31
- Completion
- 2033-07-31
- First posted
- 2026-01-22
- Last updated
- 2026-01-22
Source: ClinicalTrials.gov record NCT07357948. Inclusion in this directory is not an endorsement.